dr. (Margreet) MG Franken

Visiting fellow Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Burg. Oudlaan 50, Rotterdam
Email: franken@eshpm.eur.nl

More information

Profile

Margreet Franken, PhD is a senior researcher at the institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands. She obtained a Bachelor degree in Nursing (1992), after which she specialised in coronary (1995) and intensive care nursing (1998). From 1992 until 2008 she worked as a quality care manager, clinical nurse educator, and specialised coronary and intensive care nurse in hospitals in Arnhem, Rotterdam and Christchurch (New Zealand). In 2008, Margreet obtained a masters degree (cum laude) in Health Economics, Policy and Law from the Erasmus University in Rotterdam. Since this time she has been working as a researcher at the institute for Medical Technology Assessment of the institute of Health Policy and Management at the Erasmus University in Rotterdam. In 2014, Margreet obtained her PhD on drug reimbursement decision making. She has been involved in setting up several patient registries in oncology. Her research interests are in the field of health economics and include drug reimbursement policies and outcomes research using real-world data. She is currently involved in disease registries for melanoma, multiple myeloma, colon and lung cancer.

E. E.A.P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P.M. Suijkerbuijk, M. J. Boers-Sonderen, G. A.P. Hospers, J. W.B. de Groot, A. J.M. van den Eertwegh, M. J.B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W.P.J. van den Berkmortel, E. Oomen de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B.A.G. Haanen & A. A.M. van der Veldt (2021) - Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma - BMC Cancer, 21 (1) - doi: 10.1186/s12885-021-08018-w
Margreet Franken, Tim Kanters, JL Coenen, P De Jong, Agnes Jager & Carin Groot (2020) - Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab - Breast, 52, 71-77 - doi: 10.1016/j.breast.2020.05.001
Brenda Leeneman, Carin Groot, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JW de Groot, KH Herbschleb, JJ van der Hoeven, GA Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, Astrid Veldt, G Vreugdenhil, M Wouters, J Haanen & Margreet Franken (2020) - Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs - Cancers, 12 (4) - doi: 10.3390/cancers12041003
SA Blankenstein, MJB Aarts, F van den Berkmortel, MJ Boers-Sonderen, AJM Van den Eertwegh, Margreet Franken, J Groot, J Haanen, GA Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, Astrid Veldt, G Vreugdenhil, M Wouters & ACJ Akkooi (2020) - Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy - Cancers, 12 (5) - doi: 10.3390/cancers12051176
E van Beeck, Margreet Franken & Marco Varkevisser (2019) - Maak artsen al vroeg kostenbewust - Medisch Contact, 11, 18-20 - [link]
A Jochems, MK van der Kooij, M Fiocco, MG Schouwenburg, MJB Aarts, ACJ Akkooi, F van den Berkmortel, CU Blank, AJM Van den Eertwegh, Margreet Franken, JB de Groot, J Haanen, GA Hospers, RH Koornstra, Wim Kruit, M Louwman, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, G Vreugdenhil, M Wouters, MCT van Zeijl, KJM van der Hoeven & E Kapiteijn (2019) - Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry - Cancers, 11 (7) - doi: 10.3390/cancers11071007
Margreet Franken, Brenda Leeneman, Maria Gheorghe, Carin Groot, JBAG Haanen & Pieter Baal (2019) - A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma - European Journal of Cancer, 123, 58-71 - doi: 10.1016/j.ejca.2019.08.032 - [link]
Hedwig Blommestein, CHY van Beurden-Tan, Margreet Franken, Carin Groot, Pieter Sonneveld & S Zweegman (2019) - Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis - Haematologica, 104 (5), 1026-1035 - doi: 10.3324/haematol.2018.206912
Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - European Journal of Surgical Oncology, 45 (5), 825-831 - doi: 10.1016/j.ejso.2019.01.225 - [link]
Margreet Franken, Tim Kanters, JL Coenen, P De Jong, HR Koene, Elly Lugtenburg, Agnes Jager & Carin Groot (2018) - Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands - Anti-Cancer Drugs, 29 (8), 791-801 - doi: 10.1097/CAD.0000000000000648
MG Schouwenburg, A Jochems, Brenda Leeneman, Margreet Franken, AJM Van den Eertwegh, J Haanen, MCT van Zeijl, MJ Aarts, ACJ Akkooi, F van den Berkmortel, WAM Blokx, JWB de Groot, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MWJ Louwman, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, G Vreugdenhil, M Wouters & JJM van der Hoeven (2018) - Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes - Melanoma Research, 28 (4), 326-332 - doi: 10.1097/cmr.0000000000000453
Margreet Franken, Brenda Leeneman, A Jochems, MG Schouwenburg, MJB Aarts, ACJ Akkooi, F van den Berkmortel, AJM Van den Eertwegh, JWB de Groot, JJM van der Hoeven, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, KPM Suijkerbuijk, AJ ten Tije, G Vreugdenhil, MWJM Wouters, M Zeijl, JBAG Haanen & Carin Groot (2018) - Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands - Anti-Cancer Drugs, 29 (6), 579-588 - doi: 10.1097/CAD.0000000000000628
A Jochems, Brenda Leeneman, Margreet Franken, MG Schouwenburg, MJB Aarts, Alexander Akkooi, F van den Berkmortel, AJM Van den Eertwegh, G Groenewegen, JWB de Groot, JBAG Haanen, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, AJ ten Tije, G Vreugdenhil, MWJM Wouters, Carin Groot & JJM van der Hoeven (2018) - Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands - Anti-Cancer Drugs, 29 (6), 572-578 - doi: 10.1097/CAD.0000000000000629
Margreet Franken, Isaac Corro Ramos, Jeanine Los & Maiwenn Al (2018) - The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios - BMC Family Practice, 19 (31) - doi: 10.1186/s12875-018-0714-9 - [link]
Chrissy Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma - Journal of Clinical Oncology, 35 (12), 1312-+ - doi: 10.1200/jco.2016.71.1663
CHY van Beurden-Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Reply to X. Armoiry et al - Journal of Clinical Oncology, 35 (25), 2976 - doi: 10.1200/JCO.2017.73.7569
A Jochems, MG Schouwenburg, Brenda Leeneman, Margreet Franken, AJM Van den Eertwegh, J Haanen, H Gelderblom, Carin Groot, MJB Aarts, F van den Berkmortel, WAM Blokx, MC Cardous-Ubbink, G Groenewegen, JWB de Groot, GAP Hospers, E Kapiteijn, RH Koornstra, Wim Kruit, MW Louwman, D Piersma, RS van Rijn, AJ ten Tije, G Vreugdenhil, MWJM Wouters & JJM van der Hoeven (2017) - Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands - European Journal of Cancer, 72, 156-165 - doi: 10.1016/j.ejca.2016.11.021
Margreet Franken, E Heintz, A Gerber-Grote & J Raftery (2016) - Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries - Value in Health, 19 (8), 951-956 - doi: 10.1016/j.jval.2016.08.001
Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
JG (Jennifer G.) Gaultney, Margreet Franken, Carin Groot, Ken Redekop, PC Huijgens, Ronnie Holt, HM Lokhorst & Pieter Sonneveld (2015) - Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement - Health Policy, 119 (2), 186-194 - doi: 10.1016/j.healthpol.2014.11.010
Hedwig Blommestein, Margreet Franken & Carin Groot (2015) - A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry - Pharmacoeconomics (Print) - doi: 10.1007/s40273-015-0260-4
Margreet Franken, Elly Stolk, T Scharringhausen, A de Boer & Marc Koopmanschap (2014) - A comparative study of the role of disease severity in drug reimbursement decision making in four European countries - Health Policy, 119 (2), 195-202 - doi: 10.1016/j.healthpol.2014.10.007
Margreet Franken, Marc Koopmanschap & Adri Steenhoek (2014) - Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? - Elsevier, 108 (7), 383-389 - doi: 10.1016/j.zefq.2014.06.016
Hedwig Blommestein, Margreet Franken, Silvia Verelst, M (Michel) van Agthoven, PC Huijgens & Carin Groot (2014) - Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? - Netherlands Journal of Medicine, 72 (4), 235-241 - [link]
Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
Margreet Franken, Chantal Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010
Margreet Franken, F Nilsson, FG (Frank) Sandmann, A Boer & Marc Koopmanschap (2013) - Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making - Pharmacoeconomics (Print), 31 (9), 781-797 - doi: 10.1007/s40273-013-0074-1
FG (Frank) Sandmann, Margreet Franken & Adri Steenhoek (2013) - Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time - Health Policy, 112 (3), 285-296 - doi: 10.1016/j.healthpol.2013.03.006
Margreet Franken & XHE Koolman (2013) - Health system goals: A discrete choice experiment to obtain societal valuations - Health Policy, 112 (1-2), 28-34 - doi: 10.1016/j.healthpol.2012.12.013
JG (Jennifer G.) Gaultney, Margreet Franken, Siok Swan Tan, Ken Redekop, PC Huijgens, Pieter Sonneveld & Carin Groot (2013) - Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents - Journal of Clinical Pharmacy and Therapeutics, 38, 41-47 - doi: 10.1111/jcpt.12020
Margreet Franken, M le Polain, I Cleemput & Marc Koopmanschap (2012) - SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS - International Journal of Technology Assessment in Health Care, 28 (4), 349-357 - doi: 10.1017/S0266462312000530
I Cleemput, Margreet Franken, Marc Koopmanschap & M le Polain (2012) - EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL - International Journal of Technology Assessment in Health Care, 28 (4), 358-366 - doi: 10.1017/S0266462312000529
Siok Swan Tan, Chantal Gils, Margreet Franken, Leona Roijen & Carin Groot (2010) - The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology - Value in Health, 13 (6), 712-719 - doi: 10.1111/j.1524-4733.2010.00740.x

Marc Koopmanschap, Hans Severens & Margreet Franken (2012) - Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding - Economisch-Statistische Berichten, 97 (4644S), 36-39
Adri Steenhoek, Marc Koopmanschap, Margreet Franken & FFH Rutten (2010) - Nieuwe geneesmiddelen: niet goed, geld terug? - Nederlands Tijdschrift voor Geneeskunde, 154 (A2042), 1-5

Margreet Franken (2014) - Decision Making in Drug Reimbursement - EUR

Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA
M le Polain, Margreet Franken, Marc Koopmanschap & I Cleemput (2010) - Drug reimbursement systems: international comparison and policy recommendations - Federaal Kenniscentrum voor de gezondheidszorg - Centre fédéral d'expertise des soins de santé